Media Summary: WSH: Desmond scores on single, error in first. WATCH IN 720 HD (it makes much better, trust me!) ----------------------------------------------- Ok, this is the last video of the year
WSH: Desmond scores on single, error in first. WATCH IN 720 HD (it makes much better, trust me!) ----------------------------------------------- Ok, this is the last video of the year
CLE@KC:
BAL@CLE:
7
TB@CLE:
CLE@BAL:
CLE@STL:
CIN@CLE:
MIN@CLE:
CLE@NYY:
CLE@CWS:
NYY@CWS:
WSH@ATL: Desmond scores on single, error in first.
CLE@CWS:
CLE@DET:
TEX@CLE:
WATCH IN 720 HD (it makes much better, trust me!) ----------------------------------------------- Ok, this is the last video of the year
CLE@CWS:
http://17083.qualityrvs.net/
Nov 21, 2025 · 塞瓦替尼 (Sevabertinib，研发代号BAY2927088)是拜耳研发的口服小分子HER2选择性酪氨酸激酶抑制剂 (TKI)，此前已获FDA突破性疗法认定，用于治疗既往接受过全身治疗的不可切除或...
Jun 12, 2025 · Nuvation Bio今日宣布，美国FDA批准其下一代口服ROS1酪氨酸激酶抑制剂（TKI）Ibtrozi（taletrectinib）用于治疗局部晚期或转移性ROS1阳性（ROS1+）非小细胞肺 …
Jun 12, 2025 · Nuvation Bio今日宣布，美国FDA批准其下一代口服ROS1酪氨酸激酶抑制剂（TKI）Ibtrozi（taletrectinib）用于治疗局部晚期或转移性ROS1阳性（ROS1+）非小细胞肺 …
Jun 12, 2025 · Nuvation Bio今日宣布，美国FDA批准其下一代口服ROS1酪氨酸激酶抑制剂（TKI）Ibtrozi（taletrectinib）用于治疗局部晚期或转移性ROS1阳性（ROS1+）非小细胞肺 …
Jan 23, 2026 · 2025年，美国FDA共批准46种新型药物，其中小分子药物占31种（67%），肿瘤学领域获批数量最多达9种。 29%的获批小分子药物为同类首创疗法，22%通过加速审批途径获得批准。 本 …
